β-Glucan Subverts the Function of Myeloid Cells in Neonates

Figure 3

β-glucan-derived PMN-MDSCs produced lower levels of ROS and Arg1. Neonatal mice at postnatal days 3–4 were injected intraperitoneally with 0.5 mg of β-glucan in 50 μl of PBS, or with PBS as a control. Mice were sacrificed and spleen cells were analyzed at day 3 after β-glucan treatment. (a) Representative flow cytometry histogram (left) and mean fluorescence intensity (MFI, right) of ROS expression in PMN-MDSCs at day 3 after β-glucan treatment (n = 6 from two independent experiments). (b) The expression of Arg1 in PMN-MDSCs were measured by qRT-PCR (n = 3). (c) Volcano plot comparing differentially expressed genes from neonatal PMN-MDSCs, was analyzed using RNA-seq system. Red and blue dots represented up-regulated and down-regulated genes in β-glucan treatment PMN-MDSCs, and gray dots represented genes were not significant (n = 2). (d) Heatmap as determined by RNA-seq showing the selected gene expressions in the PMN-MDSCs from β-glucan treatment neonatal mice (n = 2). (e) The Kyoto Encyclopedia of genes and genomes (KEGG) plot showing the top enrichment pathways in PMN-MDSCs as determined by RNA-seq (n = 2). (f) gene ontology (GO) analysis of top expressed pathways in PMN-MDSCs as determined by RNA-seq (n = 2). Data represented mean ± SEM. and .

(a)

(b)

(c)

(d)

(e)

(f)